Primary Care CME Courses
Primary Care CME Courses
Comprehensive Review of Family Medicine features experts in the practice of family medicine who detail the latest developments, diagnostic guidelines, and therapeutic strategies. Led by Donald B. Middleton, MD, this CME course includes 79 case-based lectures on topics like hypertension, osteoporosis, gastroesophageal reflux disease, incontinence in women, pelvic masses, eating disorders, and more. It will help you to better:
- List pharmacologic and non-pharmacologic treatments for sports injuries
- Compare management strategies for acute and chronic pain
- Identify common and uncommon medical complications of pregnancy
- Summarize the current therapies for arthritis
- Recognize and explain life-style strategies for averting obesity
- Classify childhood and adult immunizations
This CME program offers a broader approach to treating patients with dermatology needs on an ongoing basis, stressing practical problem-solving and disease management. Focused on total patient care — from diagnosis of common skin conditions and lesions, to developing a treatment plan and establishing skin care management — Dermatology for Primary Care faculty will:
- Define fundamentals of the dermatologic exam, using real-patient photography to illustrate skin conditions from common acne and eczema to melanoma and other skin cancers
- Pull from real-patient examples to demonstrate common patterns of presentation
- Discuss how to approach patients who don’t improve and what adjustments to make when conditions change
Intensive Review of Nephrology is a case-based, comprehensive look at new developments and updates in the field. Led by renowned nephrologists, lecturers shed light on state-of-the-art practices, clinical challenges, and a wide array of topics, including membranous nephropathy, acidosis, alkalosis, genetics and kidney disease, pediatric nephrology, acute kidney injury syndromes, geriatric nephrology, and more. This CME program will help you to better:
- Summarize currently recommended nephrology guidelines
- Explain the differential diagnosis of complex clinical presentations of renal disorders
- Incorporate current therapeutic options for specific renal disorders
- Interpret up-to-date literature relevant to clinical practice
- Describe pathophysiological mechanisms for renal disease management
- Prepare for ABIM Nephrology certification/recertification examinations
Stay Abreast of Advances in Neurological Medicine
As new neurological therapeutics become available, it can be difficult for the non-neurologist to stay abreast. It is important that these clinicians — often the first a patient consults — are familiar with the epidemiology, pathophysiology, diagnosis, management, and prognosis associated with neurological conditions.
Neurology for Non-Neurologists covers the full scope of clinical neurology: commonly encountered patient complaints such as dizziness, back pain, seizures, and movement disorders, as well as special, common topics that can be mis- or underdiagnosed. Speakers in this online CME course are highly skilled with vast experience educating non-neurologists.
Evaluate and Treat Sports-Related Injuries with Confidence
In Sports Medicine for Primary Care, you’ll learn to recognize, diagnose, and treat sports medicine injuries you encounter on the field or in the office. Get up to speed on current treatment protocols and return-to-play guidelines, and earn CME credits from your home or office with this specialty review course from Oakstone. Benefit from the expertise of American Sports Medicine Institute specialists who help you:
- Evaluate emergent and non-emergent injuries
- Gain knowledge on spinal and extremity injuries, concussions, cardiac issues, infections common in sports, nutrition, heat illness, tendon injuries, and issues specific to the female athlete
- Learn regenerative medicine options for chronic injuries where other treatments have failed
- Effectively cover a sporting event, including sideline coverage, with the proper diagnostic, treatment and testing tools (including sideline concussion tests)
UCSF Advances in Internal Medicine is extremely thorough and helps you keep up with recent developments and current trends in the field. Led by H. Quinny Cheng, MD, it covers a wide range of topics in 11 subspecialty areas, including cardiology, geriatrics, endocrinology, gastroenterology, women's health, pulmonology, neurology, and more. This CME program will help you to better:
- Illustrate adept management of chronic medical problems such as hyperlipidemia, diabetes, osteoporosis, gout, and chronic pain
- Manage acute conditions such as skin and soft tissue infections, STDs, and sports-related injuries
- Effectively diagnose and treat medical problems usually treated by specialists, such as heart failure, hepatitis B & C, end-of-life care, and rheumatoid arthritis
- Integrate recent guidelines and current evidence into daily practice relevant to atrial fibrillation, coronary artery disease, anticoagulation management, chronic kidney disease, and preoperative medical evaluation
Colorectal cancer (CRC) is the third-leading cause of cancer deaths in the U.S. While a majority of patients are diagnosed before their disease has metastasized, a fifth of patients have advanced disease at the time of diagnosis. Early detection and screening have been shown to significantly reduce CRC mortality, and screening is widely recommended for average-risk adults beginning at age 50 years, (as well as earlier for individuals at higher risk). Since the mid-1990s, the U.S. Preventive Services Task Force, American Cancer Society, and other groups have recommended several modalities for screening: fecal occult blood testing (FOBT), flexible sigmoidoscopy, colonoscopy, and barium enema. Recent years have seen the addition of newer screening technologies, including stool DNA, computed tomographic colonography, and capsule endoscopy.
By the end of the session the participant will be able to:
- Describe present the current practice guideline recommendations with respect to colorectal cancer screening, including colonoscopy preparation, and apply them to patient cases
- Identify the treatment modalities currently available for management of mCRC and apply them to patient cases using evidence-based medicine
- Evaluate a treatment plan for a specific patient with mCRC to optimize safety, efficacy, and tolerability, suggesting modifications for improvement
- Describe the challenges and barriers to care associated with treating patients with mCRC
By the end of the session the participant will be able to:
- Describe the epidemiology of AUD and outline current and evolving diagnostic criteria
- Describe challenges to the successful identification of patients with AUD
- Identify the treatment modalities currently available for management of AUD and apply them to patient cases using evidence-based medicine
- Develop strategies for recognizing and improving therapeutic adherence in patients treated for AUD
Alcohol use disorder (AUD), referred to colloquially as alcoholism, is an integration of past terms that have include in past as alcohol dependence or abuse, and may be marked by any one of a number of different symptoms or behaviors that include physical cravings, compulsion, guilt, and frequent consumption over an extended period of time. There are about 7.9 million people in the United States who suffer from the disease, but a fraction – 2.2 million people – seek treatment for it. The number of people who are considered heavy drinkers is about double at somewhere between 15.9 and 17.6 million, and just under a quarter of Americans over age 12 reports having engaged in binge drinking at least once in the last month. Alcohol accounts for over 687,000 emergency department visits by people under age 20 per year, and AUD is estimated to cost $223.5 billion per year. Worldwide, 76.3 million people are estimated to have AUDs, and they account for an annual mortality rate of 1.8 million. AUD is largely undertreated, constituting one gap in care and justifying CME
Developed by TMCI Global and the Society of Cannabis Clinicians (SCC), the Clinical Cannabinoid Medicine Curriclum is the first comprehensive, online CME-certified curriculum designed to educate the practicing clinician on both the research and clinical practice aspects of the therapeutic use of cannabis. Each course within the curriculum offers up to 1.5 AMA PRA Category 1 Credits™ and the complete curriculum is certified for up to 13 CME credits.
You Will Learn About
- The fundamentals of the Endocannabinoid System
- The use of cannabis in a clinical setting
- The delivery and dosage of medical cannabis
- Mental health and the psychiatric application of medical cannabis
* Includes a bonus module on Cannabinoid Chemistry authored by Dr. Raphael Mechoulam, a professor of Medicinal Chemistry at the Hebrew University of Jerusalem in israel and leading authority on Medical Cannabis science.
Target Audience: All healthcare practitioners; the curriculum was designed to educate the practicing clinician on both the research and clinical practice aspects of the therapeutic use of cannabis.
Purchase grants one learner one year’s access to lessons and quizzes (access expires 365 days from date of course activation).
By the end of the session the participant will be able to:
- Describe the role of the immune system in cancer and cancer therapy in metastatic melanoma.
- Distinguish between the different forms of therapy presently approved for metastatic melanoma and apply them to practice, taking into account the following: treatment modalities and the recent clinical trial evidence supporting them.
- Describe emerging (investigational) therapies for metastatic melanoma
- Describe the challenges and barriers to care associated with treating patients with metastatic melanoma
Learning Objectives:
- Summarize the most impactful findings presented at ASCO 2017 relating to Metastatic Melanoma and apply them to patient cases, taking into account any relevant barriers to care.
- Additional objectives to be dictated by clinical content
By the end of the session the participant will be able to:
- Apply screening criteria to a patient receiving AI therapy or androgen deprivation therapy
- Describe the criteria for initiation of pharmacotherapy in a patient receiving AI therapy or androgen deprivation therapy and apply them to a patient case
- Identify present pharmacotherapeutic treatments for management of a patient receiving AI therapy or androgen deprivation therapy, and describe their mechanisms of action and place in therapy
- Describe the challenges associated with treating patients receiving AI or androgen deprivation therapies, focus specifically on the risks (e.g., adverse drug reactions, drug interactions, et cetera) of the agents and apply the information in optimizing patient care in a patient case
By the end of the session the participant will be able to:
- Describe the underlying pathophysiological and typical clinical features of pediatric GHD as they pertain to therapeutic targets
- Describe the optimal approach in diagnosing pediatric GHD and apply it to a patient case
- Given a patient with pediatric GHD, design a pharmacotherapeutic regimen based on his or her clinical presentation
- Evaluate patient cases during follow-up visits, including during transition therapy to adulthood when relevant, in a manner that optimizes one or more of the following: efficacy, safety, quality of life, or patient education and adherence
- Describe best practices in tracking response to pediatric GHD therapy
By the end of the session the participant will be able to:
- Describe the role of the immune system in cancer and cancer therapy in metastatic melanoma.
- Distinguish between the different forms of therapy presently approved for metastatic melanoma and apply them to practice, taking into account the following: treatment modalities and the recent clinical trial evidence supporting them.
- Describe emerging (investigational) therapies for metastatic melanoma
- Describe the challenges and barriers to care associated with treating patients with metastatic melanoma
Some have suggested that criteria used for the past two decades are inadequate for addressing the disease burden of RA because by the time a physician detects rheumatoid nodules or radiographic erosion, the optimal time has passed for treatment initiation, representing a gap in care relating to diagnosis of disease. Another potential gap is illustrated by studies in which researchers demonstrated that a systematic, objective approach to therapy with Disease Activity Score-driven therapy yields superior outcomes to routine care.
By the end of the session the participant will be able to:
- Describe the pathophysiology of RA such that it might inform treatment mechanisms.
- Describe professional guideline recommendations’ approaches to the diagnosis and treatment of RA and, where applicable, apply them to patient cases
- Identify the currently available and emerging pharmacotherapeutic treatments for management of RA and apply them to patient cases using evidence-based medicine.
- Evaluate a treatment plan for a specific patient with RA to optimize safety and efficacy, suggesting modifications for improvement, including the management of comorbidities.
- Describe the challenges and barriers to care associated with treating patients with RA.
- Using empirically valid clinical parameters to assess and operationalize acute suicidal risk
- Taking immediate actions to manage the risk of suicidal behavior
- Referring patients with suicidal ideation to behavioral health clinicians